Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in the upcoming Jefferies London Healthcare ...

HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved functional ...

50% of patients (3/6) with baseline HBsAg <1000 IU/mL achieved a functional cure (defined as sustained HBsAg loss and HBV DNA ...

Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts assessed previously23% of participants ...

HOPE not hate can reveal the location of plots of land in Wales owned by the Woodlander Initiative, a land-buying scheme with ...

Nativity of Our Lord Parish will hold their annual “Thanksgiving Dinner with All the Trimmings” on Thursday, Nov. 28 at 2:00 ...

Jefferies London Healthcare Conference: Fireside Chat on November 21, 2024 at 12:00 pm GMT / 7:00 am EST To access the live ...

Arbutus has moved into Part 3 of this clinical trial which evaluates repeat dosing of AB-101 for 28 days in patients with cHBV and expects to report preliminary data in the first half of next year.

Good evening, Pennsylvania Patch readers! We've assembled some of the most share-worthy stories from across the state. These ...

WARMINSTER, Pa. (WPVI) -- A SEPTA transit police officer is off the job after being charged with the distribution of child ...